131 related articles for article (PubMed ID: 16642693)
1. [In high risk patients also treat high normal blood pressure values!].
Düsing R
MMW Fortschr Med; 2006 Mar; 148(13):5. PubMed ID: 16642693
[No Abstract] [Full Text] [Related]
2. [Preventing hypertension with drugs?].
MMW Fortschr Med; 2006 Mar; 148(13):4-5. PubMed ID: 16642692
[No Abstract] [Full Text] [Related]
3. Arterial 'prehypertension': a useful concept for drug companies, useless for patients.
Prescrire Int; 2007 Apr; 16(88):73-5. PubMed ID: 17460859
[TBL] [Abstract][Full Text] [Related]
4. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Weisser B; Gerwe M; Braun M; Funken C
Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure variability: the challenge of variation.
Marshall TP
Am J Hypertens; 2008 Jan; 21(1):3-4. PubMed ID: 18091733
[No Abstract] [Full Text] [Related]
6. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].
Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
MMW Fortschr Med; 2008 Feb; 150(6):40. PubMed ID: 18323344
[No Abstract] [Full Text] [Related]
7. [Treatment of high-normal blood pressure with angiotensin receptor blockers. TROPHY Study (Trial of Preventing Hypertension)].
Mann J
Internist (Berl); 2007 Apr; 48(4):436-8. PubMed ID: 17342351
[No Abstract] [Full Text] [Related]
8. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial.
Saxby BK; Harrington F; Wesnes KA; McKeith IG; Ford GA
Neurology; 2008 May; 70(19 Pt 2):1858-66. PubMed ID: 18458219
[TBL] [Abstract][Full Text] [Related]
9. [JNC 7].
Takeda K
Nihon Rinsho; 2006 Aug; 64 Suppl 6():549-55. PubMed ID: 16981589
[No Abstract] [Full Text] [Related]
10. Renin-angiotensin system blockade safely reduces blood pressure in patients with minor ischemic stroke during the acute phase.
Nakamura T; Tsutsumi Y; Shimizu Y; Uchiyama S
J Stroke Cerebrovasc Dis; 2010; 19(6):435-40. PubMed ID: 20702114
[TBL] [Abstract][Full Text] [Related]
11. [Blood pressure limits for the initiation and goal of antihypertensive therapy. Blood pressure and cardiovascular risk].
Holzgreve H
MMW Fortschr Med; 2005 Jun; 147(23):37-8. PubMed ID: 15981903
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus.
Kaku K; Enya K; Sugiura K; Totsuka N
Curr Med Res Opin; 2011 Nov; 27 Suppl 3():73-84. PubMed ID: 22106979
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study.
Turner MJ; van Schalkwyk JM
Am J Hypertens; 2008 Jan; 21(1):85-91. PubMed ID: 18091749
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure lowering does not reduce risk of cardiovascular events in patients at intermediate risk.
Torjesen I
BMJ; 2016 Apr; 353():i1899. PubMed ID: 27044631
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension--the Nifedipine and Candesartan Combination (NICE-Combi) Study.
Fujikawa K; Hasebe N; Kikuchi K;
Hypertens Res; 2005 Jul; 28(7):585-91. PubMed ID: 16335887
[TBL] [Abstract][Full Text] [Related]
16. A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension.
Karlson BW; Zetterstrand S; Olofsson B; Elmfeldt D
Blood Press; 2009; 18(3):149-56. PubMed ID: 19462314
[TBL] [Abstract][Full Text] [Related]
17. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ].
Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
MMW Fortschr Med; 2008 Jan; 149 Suppl 4():172-81. PubMed ID: 18402243
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
[TBL] [Abstract][Full Text] [Related]
20. Choice of treatment: outcomes and treatment goals.
Temple RJ
Am Heart J; 2003 Oct; 146(4):565-7. PubMed ID: 14564306
[No Abstract] [Full Text] [Related]
[Next] [New Search]
